|
ZHEJIANG HISUN PHARMACEUTICAL CO.,LTD.
|
Linezolid has sufficient capacity for stable supply, has passed CDE review and has been submitted to US. As a comprehensive pharmaceutical enterprise with complete research, production and marketing value chain and multi-region development, Hisun Pharmaceutical owns three major production bases of APIs, with perfect production lines covering nearly 100 varieties, and is one of the important producers of speciality APIs in the world.
Hisun Pharmaceutical is equipped with advanced production equipment and facilities and testing instruments, and its production, testing and release follow the requirements of GMP; Hisun Pharmaceutical has a central research institute at its headquarters in Taizhou, a nationally-recognised enterprise technology centre, a provincial academician's workstation, and the first postdoctoral scientific research station in the province with independent enrolment qualification; the R&D platform is equipped with a R&D laboratory and a small and medium-sized pilot plant, which provides seamless linkage between the development and industrialisation of new products and new processes. The R&D platform is equipped with R&D laboratories and small and medium-sized pilot production workshops, providing a seamless connection from new product and process development to industrialisation.
Hisun Pharmaceutical is equipped with a professional quality management team and a perfect quality management system, covering the whole life cycle of drug quality;
The pharmaceutical administration system of Hisun Pharmaceutical can efficiently support the global registration affairs of customers and provide better products and services for global customers;
Hisun Pharmaceutical establishes an EHS laboratory, equipped with a professional research team and advanced experimental equipment, a perfect EHS integrated management system and a professional EHS management team to escort the company's safe production and green development. The laboratory management system passed CNAS certification in 2018.
Hisun Pharmaceutical adheres to the development concept of "no best, only better", and looks forward to working with you hand in hand! |
Send Inquiry
|
|
ZHEJIANG HISUN PHARMACEUTICAL CO.,LTD.
|
Linezolid is indicated in adults and children for the treatment of infections caused by susceptible Gram-positive bacteria, including nosocomial pneumonia, community-acquired pneumonia, skin and skin structure infections, and vancomycin-resistant _Enterococcus faecium_ infections. Examples of susceptible bacteria include _Staphylococcus aureus_, _Streptococcus pneumoniae_, _Streptococcus pyogenes_, and _Streptococcus agalactiae_. Linezolid is not indicated for the treatment of Gram-negative infections, nor has it been evaluated for use longer than 28 days. |
Send Inquiry
|
Pharma Sources Insight June 2024: Globalization on the Go
